Santen Pharmaceutical Co Ltd (4536.T)
4536.T on Tokyo Stock Exchange
1,512JPY
23 Jan 2019
1,512JPY
23 Jan 2019
Change (% chg)
¥-11 (-0.72%)
¥-11 (-0.72%)
Prev Close
¥1,523
¥1,523
Open
¥1,518
¥1,518
Day's High
¥1,523
¥1,523
Day's Low
¥1,505
¥1,505
Volume
1,036,400
1,036,400
Avg. Vol
1,210,215
1,210,215
52-wk High
¥2,061
¥2,061
52-wk Low
¥1,470
¥1,470
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Sep | 57,861.00 | 18.437 |
| Jun | 56,483.00 | 16.794 | |
| FY 2018 | Mar '18 | 56,350.00 | 19.396 |
| Dec | 57,817.00 | 29.598 | |
| Sep | 54,826.00 | 15.300 | |
| Jun | 55,949.00 | 22.122 | |
| FY 2017 | Mar '17 | 48,429.00 | 11.201 |
| Dec | 52,838.00 | 11.399 | |
| Sep | 47,823.00 | 12.478 | |
| Jun | 50,006.00 | 17.613 |
*Note: Units in Millions ofYen
**Note: Units in Yen
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 1 | 59,400.00 | 59,400.00 | 59,400.00 | -- |
| Quarter Ending Mar-19 | 3 | 62,032.30 | 63,841.00 | 60,956.00 | -- |
| Year Ending Mar-19 | 11 | 237,230.00 | 240,332.00 | 233,700.00 | 228,357.00 |
| Year Ending Mar-20 | 11 | 250,369.00 | 260,000.00 | 244,550.00 | 241,382.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 1 | 22.12 | 22.12 | 22.12 | -- |
| Quarter Ending Mar-19 | 2 | 17.99 | 18.48 | 17.51 | -- |
| Year Ending Mar-19 | 12 | 78.39 | 88.58 | 68.50 | 75.76 |
| Year Ending Mar-20 | 12 | 84.84 | 98.30 | 74.70 | 84.60 |
| LT Growth Rate (%) | 1 | 3.70 | 3.70 | 3.70 | 10.18 |
Sales and Profit Figures in Japanese Yen (JPY);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 28.99 | 30.49 | 33.71 | |
| P/E High - Last 5 Yrs. | 30.21 | 45.03 | 49.93 | |
| P/E Low - Last 5 Yrs. | 13.18 | 23.66 | 24.27 | |
| Beta | 0.58 | 0.90 | 0.90 | |
| Price to Sales (TTM) | 3.46 | 4.12 | 6.28 | |
| Price to Book (MRQ) | 2.73 | 5.11 | 5.27 | |
| Price to Tangible Book (MRQ) | 4.49 | 5.85 | 6.78 | |
| Price to Cash Flow (TTM) | 20.38 | 24.01 | 24.84 | |
| % Owned Institutions | -- | 0.91 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | 1.49 | 1.49 | 1.40 | |
| Dividend Yield - 5 Year Avg | 1.65 | 1.51 | 1.42 | |
| Dividend 5 Year Growth Rate | 5.39 | 4.13 | 4.83 | |
| Payout Ratio(TTM) | 43.17 | 43.96 | 41.08 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 11.88 | 4.31 | 9.73 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 3.91 | 4.15 | 5.88 | |
| Sales - 5 Yr. Growth Rate | 11.72 | 10.87 | 11.20 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 24.23 | 45.05 | 47.26 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -52.93 | -- | -- | |
| EPS - 5 Yr. Growth Rate | 7.31 | 10.28 | 10.82 | |
| Capital Spending - 5 Yr. Growth Rate | 23.70 | 15.84 | 15.18 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 2.62 | 2.15 | 2.25 |
| Current Ratio (MRQ) | 3.16 | 2.98 | 3.08 |
| LT Debt to Equity (MRQ) | 2.37 | 8.86 | 11.39 |
| Total Debt to Equity (MRQ) | 8.05 | 12.91 | 16.13 |
| Interest Coverage (TTM) | 47.31 | 33.85 | 29.51 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 61.88 | 53.65 | 53.79 | |
| Gross Margin - 5 Yr. Avg. | 63.12 | 51.65 | 52.17 | |
| EBITD Margin (TTM) | 21.40 | -- | -- | |
| EBITD - 5 Yr. Avg | 28.55 | 17.95 | 12.87 | |
| Operating Margin (TTM) | 16.45 | 14.28 | 6.20 | |
| Operating Margin - 5 Yr. Avg. | 24.66 | 14.22 | 8.31 | |
| Pre-Tax Margin (TTM) | 16.47 | 14.84 | 7.17 | |
| Pre-Tax Margin - 5 Yr. Avg. | 24.72 | 14.67 | 8.61 | |
| Net Profit Margin (TTM) | 12.02 | 11.08 | 3.31 | |
| Net Profit Margin - 5 Yr. Avg. | 16.64 | 11.02 | 4.89 | |
| Effective Tax Rate (TTM) | 27.04 | 23.02 | 22.88 | |
| Effective Tax Rate - 5 Yr. Avg. | 32.70 | 23.17 | 23.39 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 55,914,640 | 959,737,456 | 844,196,423 | |
| Net Income/Employee (TTM) | 6,721,026 | 113,812,018 | 100,059,031 | |
| Receivable Turnover (TTM) | 2.81 | 5.72 | 5.72 | |
| Inventory Turnover (TTM) | 2.98 | 2.61 | 3.48 | |
| Asset Turnover (TTM) | 0.63 | 0.97 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 7.53 | 11.55 | 11.08 | |
| Return on Assets - 5 Yr. Avg. | 10.07 | 12.93 | 12.21 | |
| Return on Investment (TTM) | 8.89 | 14.98 | 14.48 | |
| Return on Investment - 5 Yr. Avg. | 12.19 | 16.85 | 15.88 | |
| Return on Equity (TTM) | 9.56 | 16.30 | 15.99 | |
| Return on Equity - 5 Yr. Avg. | 13.23 | 17.76 | 17.00 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 1.95 | 10.83 | 11.72 |
| EPS (TTM) % | -56.40 | 5.54 | 7.31 |
| Dividend % | 4.00 | 9.14 | 5.39 |
Note: Units in Millions of US Dollars
Performance for Santen Pharmaceutical Co Ltd
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -2.24 | -7.67 | 99 | 22 |
| 13 Week | 13.02 | 7.65 | 99 | 39 |
| 26 Week | 15.03 | 1.57 | 99 | 33 |
| 52 Week | 14.80 | -7.87 | 99 | 9 |
| YTD | 22.03 | 9.84 | 99 | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 50.11% |
| # of Holders: | 247 |
| Total Shares Held: | 204,010,979 |
| 3 Mo. Net Change: | 11,090,202 |
| # New Positions: | 5 |
| # Closed Positions: | 2 |
| # Increased Positions: | 59 |
| # Reduced Positions: | 43 |
| # Net Buyers: | 16 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.